Biophan CEO to Present Today at the 2004 Medical Device Forum; Presentation Includes Observations on Biomedical Device Future.Business Editors/Health/Medical Writers BIOWIRE2K ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 15, 2004 Biophan Technologies, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ), an innovator, developer and marketer of advanced biomedical technology Biomedical technology involves the application of engineering and technology principles to the domain of living or biological systems. Usually biomedical denotes a greater stress on problems related to human health and diseases. , announced that Michael Weiner, president and chief executive officer of Biophan, will present today at the 2004 Leadership Forum on Medical Devices taking place in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The forum will offer a broad overview of the international medical device industry as well as in-depth analysis of some of the upcoming new technologies in this field. In addition to Mr. Weiner, announced speakers include Mr. Tomas Puusepp, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Elekta, Inc., Mr. Michael J. Neuberger, Managing Director, Investment Banking, SG Cowen Securities Corporation and Mr. Bengt Modeer, Vice President, Corporate Communications, Gambro AB. Mr. Weiner's presentation, which will be posted in its entirety on the company's website, at 4pm Eastern today, www.biophan.com, includes the following remarks: "...we see the following things on the overall biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. device horizon: -- dramatic improvements in biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. of devices... -- miniaturization min·i·a·tur·ize tr.v. min·i·a·tur·ized, min·i·a·tur·iz·ing, min·i·a·tur·iz·es To plan or make on a greatly reduced scale. min of devices... -- improvements in implantable power systems... -- Nanomagnetic materials will allow devices such as neurostimulators, which today have to be replaced every two to three years, to potentially last for the life of the patient... -- Smart stents, and smart shunts, offering expanded capabilities... -- The use of fiber-optics in the body... -- Nanomagnetic particle contrast agents yielding advances in MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. imaging. -- We expect that, in time, we will see implanted miniature lasers for diagnostics and therapeutics. -- Devices which can detect specific cell types and kill or harvest them... -- Devices which can restore full cardiac output cardiac output n. Abbr. CO The volume of blood pumped from the right or left ventricle in one minute. It is equal to the stroke volume multiplied by the heart rate. to a diseased or failed heart... Mr. Weiner concludes his presentation by noting, "We are pleased to report that we are making contributions, wherever possible, on this exciting forward horizon, to ensure these devices are all designed to not only achieve these miracles as described, but where needed, to design in MRI safety and compatibility. We see a bright future, indeed, for human beings, for the biomedical device, industry, and for Biophan." About Biophan Technologies, Inc. Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI) equipment and other sources of powerful magnetism or radio frequency signals. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed over 50 related patent applications that will help establish Biophan products as the standard of care in each of their markets. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion